Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results

被引：1

作者：

Liu, Joyce ^{[1
]}

O'Malley, David ^{[2
,3
]}

Van Nieuwenhuysen, Els ^{[4
]}

Moore, Kathleen ^{[5
]}

Hamilton, Erika ^{[6
]}

Yeku, Oladapo ^{[7
]}

Bouberhan, Sara ^{[7
]}

Hou, June ^{[8
]}

Schroeder, David ^{[9
]}

Wang, Bin ^{[10
]}

Yoo, Suk-Young ^{[10
]}

Govindraj, Shilpa ^{[11
]}

Brouwer-Visser, Jurriaan ^{[12
]}

Peterman, Mary ^{[13
]}

Schmidt, Tamara ^{[13
]}

Barnes, Brigid ^{[13
]}

Lowy, Israel ^{[13
]}

Uldrick, Thomas ^{[13
]}

Miller, Elizabeth ^{[13
]}

O'Cearbhaill, Roisin ^{[14
,15
]}

机构：

[1] Dana Farber Canc Inst, Div Gynecol Oncol, Boston, MA 02115 USA

[2] Ohio State Univ, Columbus, OH 43210 USA

[3] James Canc Ctr, Div Gynecol Oncol Obstet & Gynecol, Columbus, OH USA

[4] Leuven Canc Inst, Gynaecol & Obstet, Leuven, Belgium

[5] Univ Oklahoma, Sarah Cannon Res Inst, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA

[6] Tennessee Oncol Breast & Gynecol Canc Res, Sarah Cannon Res Inst, Nashville, TN USA

[7] Massachusetts Gen Hosp, Gynecol Oncol Program, Boston, MA USA

[8] Columbia Univ, Med Ctr, Div Gynecol Oncol, New York, NY USA

[9] Grand Hop Charleroi, Serv Oncol Hematol, Charleroi, Belgium

[10] Regeneron Pharmaceut Inc, Biostat, Tarrytown, NY USA

[11] Regeneron Pharmaceut Inc, Global Patient Safety, Tarrytown, NY USA

[12] Regeneron Pharmaceut Inc, Precis Med, Tarrytown, NY USA

[13] Regeneron Pharmaceut Inc, Oncol Clin Dev, Tarrytown, NY USA

[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[15] Weill Cornell Med Coll, Gynecol Med Oncol Serv, New York, NY USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO011LBA

引用

页码：A9 / A10

页数：2

共 50 条

[21] Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Yue Wang
Jingyi Han
Dongdong Wang
Menghua Cai
Yi Xu
Yu Hu
Hui Chen
Wei He
Jianmin Zhang
Signal Transduction and Targeted Therapy, 8
[22] Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Wang, Yue
Han, Jingyi
Wang, Dongdong
Cai, Menghua
Xu, Yi
Hu, Yu
Chen, Hui
He, Wei
Zhang, Jianmin
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
[23] Multi-omics analysis of anti-PD-1 antibody (Nivolumb) treated patients with ovarian cancer
Hamanishi, Junzo
Murakami, Ryusuke
Konishi, Ikuo
Baba, Tsukasa
Abiko, Kaoru
Matsumura, Noriomi
Yamaguchi, Ken
Mandai, Masaki
CANCER SCIENCE, 2018, 109 : 98 - 98
[24] Passenger fusion genes are correlated to antitumor effect of anti-PD-1 antibody nivolumab for ovarian cancer
Hamanishi, J.
Murakami, R.
Baba, T.
Yamaguchi, K.
Abiko, K.
Mandai, M.
GYNECOLOGIC ONCOLOGY, 2019, 154 : 86 - 86
[25] Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody
Akewanlop, C
Watanabe, M
Singh, B
Walker, M
Kufe, DW
Hayes, DF
CANCER RESEARCH, 2001, 61 (10) : 4061 - 4065
[26] A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL DOSE-ESCALATION RESULTS
Johnson, Melissa
Lakhani, Nehal
Girda, Eugenia
Olszanski, Anthony
Fong, Lawrence
Han, Hyunsil
Casey, Kerry
Li, Siyu
Visich, Jennifer
Skokos, Dmitris
Seebach, Frank
Lowy, Israel
Fury, Matthew
Mathias, Melissa
Segal, Neil
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A767 - A768
[27] Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab
Hamanishi, J.
Mandai, M.
Matsumura, N.
Abiko, K.
Baba, T.
Yamaguchi, K.
Konishi, I.
GYNECOLOGIC ONCOLOGY, 2015, 137 : 23 - 23
[28] A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.
Drake, Charles G.
Zhang, Jingsong
Stein, Mark N.
Xu, Yuanfang
Seebach, Frank A.
Lowy, Israel
Mohan, Kosalai Kal
Kroog, Glenn
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.
Zhang, Jingsong
Stein, Mark N.
Kelly, William Kevin
Tsao, Che-Kai
Falchook, Gerald Steven
Xu, Yuanfang
Seebach, Frank A.
Lowy, Israel
Mohan, Kosalai Kal
Kroog, Glenn
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[30] A PHASE I/II STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS
Lakhani, Nehal
Johnson, Melissa
Groisberg, Roman
Han, Hyunsil
Casey, Kerry
Li, Siyu
Skokos, Dimitris
Seebach, Frank
Lowy, Israel
Fury, Matthew
Mathias, Melissa
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A565 - A565

← 1 2 3 4 5 →